Can Novavax's Coronavirus Vaccine Be Valued?

Can Novavax's Coronavirus Vaccine Be Valued?

It doesn't surprise me that a small-cap biotech company like Novavax (NASDAQ:NVAX) skyrocketed when the COVID-19 pandemic began. The market opportunity is at once vast and risky (as biotech investing often is). Novavax has soared from about a $120 million market cap in January to almost a $9 billion market cap today.